Jump to content

Adenosquamous lung carcinoma: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m WP:CHECKWIKI error fixes + general fixes, added orphan tag using AWB (7641)
Citation bot (talk | contribs)
Bots
5,182,371 edits
Add: s2cid. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | #UCB_webform 15/2660
 
(31 intermediate revisions by 23 users not shown)
Line 1: Line 1:
{{Orphan|date=March 2011}}
{{Use dmy dates|date=June 2021}}
{{Infobox medical condition (new)

| name = <!--{{PAGENAME}} by default-->
⚫
'''Adenosquamous lung carcinoma''' (AdSqLC) is a biphasic [[malignant]] [[tumor]] arising from lung tissue that is composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.<ref name='who2004'>{{Cite book|title=Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart |editor1-last=Travis |editor1-first=William D |editor2-last=Brambilla |editor2-first=Elisabeth |editor3-last=Muller-Hermelink |editor3-first=H Konrad |editor4-last=Harris |editor4-first=Curtis C |publisher=IARC Press |location=Lyon |year=2004 |series=World Health Organization Classification of Tumours |isbn=92 832 2418 3 |url=http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/bb10-cover.pdf |accessdate=27 March 2010}}</ref>
| synonym =
| image =
| image_size =
| alt =
| caption =
| pronounce =
| specialty = oncology/pulmonology
| symptoms =
| complications =
| onset =
| duration =
| types =
| causes =
| risks =
| diagnosis =
| differential =
| prevention =
| treatment =
| medication =
| prognosis =
| frequency =
| deaths =
}}
⚫
'''Adenosquamous lung carcinoma''' (AdSqLC) is a biphasic [[malignant]] [[tumor]] arising from lung tissue that is composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.<ref name='who2004'>{{Cite book |title=Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart |editor1-last=Travis |editor1-first=William D |editor2-last=Brambilla |editor2-first=Elisabeth |editor3-last=Muller-Hermelink |editor3-first=H Konrad |editor4-last=Harris |editor4-first=Curtis C |publisher=IARC Press |location=Lyon |year=2004 |series=World Health Organization Classification of Tumours |isbn=978-92-832-2418-1 |url=http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/bb10-cover.pdf |accessdate=27 March 2010 |archive-url=https://web.archive.org/web/20090823210304/http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/bb10-cover.pdf |archive-date=23 August 2009 |url-status=dead }}</ref>
__TOC__


==Classification==
==Classification==
Lung cancers have been historically classified using two major paradigms. [[Histological]] classification systems group lung cancers according to the appearance of the cells and surrounding tissues when they are viewed under a microscope. [[Clinical]] classification systems divide lung cancers into groups based on medical criteria, particularly their response to different treatment regimens.
Lung cancers have been historically classified using two major paradigms. [[Histological]] classification systems group lung cancers according to the appearance of the cells and surrounding tissues when they are viewed under a microscope. [[Illness|Clinical]] classification systems divide lung cancers into groups based on medical criteria, particularly their response to different treatment regimens.


Before the mid-1900s, lung cancer was considered to be a single disease entity, with all forms treated similarly. In the 1960s, [[small cell lung carcinoma]] (SCLC) was recognized as a unique form of lung cancer, based both on its appearance ([[histology]]) and its [[clinical]] properties, including much greater susceptibility to [[chemotherapy]] and [[radiation]], more rapid growth rate, and its propensity to metastasize widely early on in its course. Since then, most [[oncologists]] have based patient treatment decisions on a dichotomous division of lung cancers into SCLC and [[non-small cell lung carcinomas]] (NSCLC), with the former being treated primarily with chemoradiation, and the latter with surgery.
Before the mid-1900s, lung cancer was considered to be a single disease entity, with all forms treated similarly. In the 1960s, [[small cell lung carcinoma]] (SCLC) was recognized as a unique form of lung cancer, based both on its appearance ([[histology]]) and its [[Illness|clinical]] properties, including much greater susceptibility to [[chemotherapy]] and [[radiation]], more rapid growth rate, and its propensity to metastasize widely early on in its course. Since then, most [[oncologists]] have based patient treatment decisions on a [[dichotomy|dichotomous]] division of lung cancers into SCLC and [[non-small cell lung carcinomas]] (NSCLC), with the former being treated primarily with chemoradiation, and the latter with surgery.


An explosion of new knowledge, accumulated mainly over the last 20 years, has proved that lung cancers should be considered an extremely [[heterogeneous]] family of [[neoplasms]]<ref name='RoggliVollmer'>Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R. Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. Hum Pathol 1985; 16: 569-79.</ref> with widely varying genetic, biological, and clinical characteristics, particularly their responsiveness to the large number of newer treatment protocols. Well over 50 different histological variants are now recognized under the 2004 revision of the [[World Health Organization]] ("WHO-2004") typing system, currently the most widely used lung cancer classification scheme.<ref name='who2004' /> Recent studies have shown beyond doubt that the old clinical classification paradigm of "SCLC vs. NSCLC" is now obsolete, and that correct "subclassification" of lung cancer cases is necessary to assure that lung cancer patients receive optimum management.<ref name='RossiMarchioni'>Rossi G, Marchioni A, Sartori1 G, Longo L, Piccinini S, Cavazza A. Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor. Curr Resp Med Rev 2007; 3: 69-77.</ref><ref name='Vincent'>Vincent MD. Optimizing the management of advanced non-small-cell lung cancer: a personal view. Curr Oncol 2009; 16: 9-21.</ref>
An explosion of new knowledge, accumulated mainly over the last 20 years, has proved that lung cancers should be considered an extremely [[heterogeneous]] family of [[neoplasms]]<ref name='RoggliVollmer'>{{cite journal |vauthors=Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R |title=Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases |journal=Hum. Pathol. |volume=16 |issue=6 |pages=569–79 |date=June 1985|pmid=2987102 |doi=10.1016/S0046-8177(85)80106-4}}</ref> with widely varying genetic, biological, and clinical characteristics, particularly their responsiveness to the large number of newer treatment protocols. Well over 50 different histological variants are now recognized under the 2004 revision of the [[World Health Organization]] ("WHO-2004") typing system, currently the most widely used lung cancer classification scheme.<ref name='who2004' /> Recent studies have shown beyond doubt that the old clinical classification paradigm of "SCLC vs. NSCLC" is now obsolete, and that correct "subclassification" of lung cancer cases is necessary to assure that lung cancer patients receive optimum management.<ref name='RossiMarchioni'>{{cite journal |vauthors =Rossi G, Marchioni A, Sartori G, Longo L, Piccinini S, Cavazza A |title=Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor |journal=Curr Respir Med Rev |volume=3 |pages=69–77 |year=2007 |doi=10.2174/157339807779941820 }}</ref><ref name='Vincent'>{{cite journal |author =Vincent MD |title=Optimizing the management of advanced non-small-cell lung cancer: a personal view |journal=Curr Oncol |volume=16 |issue=4 |pages=9–21 |date=August 2009|pmid=19672420 |pmc=2722061 |doi=10.3747/co.v16i4.465}}</ref>


Approximately 98% of lung cancers are [[carcinoma]], which are tumors composed of cells with [[epithelial]] characteristics.<ref name='TravisTravis'>Travis WD, Travis LB, DeVesa SS. Lung Cancer. Cancer 1995; 75: 191-202.</ref> LCLC's are one of 8 major groups of lung carcinomas recognized in WHO-2004:<ref name='who2004'>{{cite book |title=Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart |editor1-last=Travis |editor1-first=William D |editor2-last=Brambilla |editor2-first=Elisabeth |editor3-last=Muller-Hermelink |editor3-first=H Konrad |editor4-last=Harris |editor4-first=Curtis C |publisher=IARC Press |location=Lyon |year=2004 |series=World Health Organization Classification of Tumours |isbn=92 832 2418 3 |url=http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/bb10-cover.pdf |accessdate=27 March 2010}}</ref>
Approximately 98% of lung cancers are [[carcinoma]], which are tumors composed of cells with [[epithelial]] characteristics.<ref name='TravisTravis'>{{cite journal |vauthors=Travis WD, Travis LB, Devesa SS |title=Lung cancer |journal=Cancer |volume=75 |issue=1 Suppl |pages=191–202 |date=January 1995|pmid=8000996 |doi=10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y|s2cid=34718856 }}</ref> LCLC's are one of 8 major groups of lung carcinomas recognized in WHO-2004:<ref name='who2004'/>
* [[Squamous cell carcinoma]]

*[[Squamous cell carcinoma]]
* [[Small cell carcinoma#Lung|Small cell carcinoma]]
⚫
* [[Adenocarcinoma]]
*[[Small_cell_carcinoma#lung|Small cell carcinoma]]
* [[Large Cell Lung Carcinoma|Large cell carcinoma]]
⚫
*[[Adenocarcinoma]]
*[[Large Cell Lung Carcinoma|Large cell carcinoma]]
* Adenosquamous carcinoma
⚫
* [[Sarcomatoid carcinoma of the lung|Sarcomatoid carcinoma]]
*Adenosquamous carcinoma
⚫
* [[Carcinoid|Carcinoid tumor]]
⚫
*[[Sarcomatoid carcinoma of the lung|Sarcomatoid carcinoma]]
⚫
* [[Salivary gland-like lung carcinoma|Salivary gland-like carcinoma]]
⚫
*[[Carcinoid|Carcinoid tumor]]
⚫
*[[Salivary gland-like lung carcinoma|Salivary gland-like carcinoma]]


==References==
==References==
{{Reflist|2}}
{{reflist}}


==External links==
==External links==
* {{cite web |title=Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart |work=World Health Organization Classification of Tumours |url=http://www.iarc.fr/en/publications/pdfs-online/pat-gen/index.php |access-date=6 March 2011 |archive-url=https://web.archive.org/web/20151115033702/http://www.iarc.fr/en/publications/pdfs-online/pat-gen/index.php |archive-date=15 November 2015 |url-status=dead }} (Download Page).
* [http://www.iarc.fr/en/publications/pdfs-online/pat-gen/index.php] World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (Download Page).
* [http://www.cancer.gov/cancertopics/types/lung] Lung cancer page at the National Cancer Institute.
* {{cite web |title=Lung cancer page |publisher=National Cancer Institute |url=http://www.cancer.gov/cancertopics/types/lung|date=1980-01-01 }}


{{Respiratory neoplasia}}
{{Respiratory neoplasia}}

{{Use dmy dates|date=March 2011}}


{{DEFAULTSORT:Adenosquamous Lung Carcinoma}}
{{DEFAULTSORT:Adenosquamous Lung Carcinoma}}
[[Category:Types of cancer]]
[[Category:Lung cancer]]
[[Category:Lung cancer]]

Latest revision as of 20:28, 13 October 2023

Adenosquamous lung carcinoma
SpecialtyOncology/pulmonology

Adenosquamous lung carcinoma (AdSqLC) is a biphasic malignant tumor arising from lung tissue that is composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells.[1]

Classification

[edit]

Lung cancers have been historically classified using two major paradigms. Histological classification systems group lung cancers according to the appearance of the cells and surrounding tissues when they are viewed under a microscope. Clinical classification systems divide lung cancers into groups based on medical criteria, particularly their response to different treatment regimens.

Before the mid-1900s, lung cancer was considered to be a single disease entity, with all forms treated similarly. In the 1960s, small cell lung carcinoma (SCLC) was recognized as a unique form of lung cancer, based both on its appearance (histology) and its clinical properties, including much greater susceptibility to chemotherapy and radiation, more rapid growth rate, and its propensity to metastasize widely early on in its course. Since then, most oncologists have based patient treatment decisions on a dichotomous division of lung cancers into SCLC and non-small cell lung carcinomas (NSCLC), with the former being treated primarily with chemoradiation, and the latter with surgery.

An explosion of new knowledge, accumulated mainly over the last 20 years, has proved that lung cancers should be considered an extremely heterogeneous family of neoplasms[2] with widely varying genetic, biological, and clinical characteristics, particularly their responsiveness to the large number of newer treatment protocols. Well over 50 different histological variants are now recognized under the 2004 revision of the World Health Organization ("WHO-2004") typing system, currently the most widely used lung cancer classification scheme.[1] Recent studies have shown beyond doubt that the old clinical classification paradigm of "SCLC vs. NSCLC" is now obsolete, and that correct "subclassification" of lung cancer cases is necessary to assure that lung cancer patients receive optimum management.[3][4]

Approximately 98% of lung cancers are carcinoma, which are tumors composed of cells with epithelial characteristics.[5] LCLC's are one of 8 major groups of lung carcinomas recognized in WHO-2004:[1]

References

[edit]
  1. ^ a b c Travis, William D; Brambilla, Elisabeth; Muller-Hermelink, H Konrad; Harris, Curtis C, eds. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (PDF). World Health Organization Classification of Tumours. Lyon: IARC Press. ISBN 978-92-832-2418-1. Archived from the original (PDF) on 23 August 2009. Retrieved 27 March 2010.
  2. ^ Roggli VL, Vollmer RT, Greenberg SD, McGavran MH, Spjut HJ, Yesner R (June 1985). "Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases". Hum. Pathol. 16 (6): 569–79. doi:10.1016/S0046-8177(85)80106-4. PMID 2987102.
  3. ^ Rossi G, Marchioni A, Sartori G, Longo L, Piccinini S, Cavazza A (2007). "Histotype in non-small cell lung cancer therapy and staging: The emerging role of an old and underrated factor". Curr Respir Med Rev. 3: 69–77. doi:10.2174/157339807779941820.
  4. ^ Vincent MD (August 2009). "Optimizing the management of advanced non-small-cell lung cancer: a personal view". Curr Oncol. 16 (4): 9–21. doi:10.3747/co.v16i4.465. PMC 2722061. PMID 19672420.
  5. ^ Travis WD, Travis LB, Devesa SS (January 1995). "Lung cancer". Cancer. 75 (1 Suppl): 191–202. doi:10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y. PMID 8000996. S2CID 34718856.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Adenosquamous_lung_carcinoma&oldid=1179996601"